Haptoglobin genotype and cerebrovascular disease incidence in type 1 diabetes

Diabetes and Vascular Disease Research

Volumn 11, Issue 5, 2014, Pages 335-342

  Costacou, Tina ^a   Secrest, Aaron M ^b   Ferrell, Robert E ^c   Orchard, Trevor J ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

coronary artery disease; haptoglobin genotype; hypertension; stroke; Type 1 diabetes

Indexed keywords

HAPTOGLOBIN; HP PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; GENE FREQUENCY; GENETICS; IMMUNOLOGY; INCIDENCE; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDY; PROTECTION; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME; UNITED STATES; YOUNG ADULT;

ADULT; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; GENE FREQUENCY; GENOTYPE; HAPTOGLOBINS; HUMANS; HYPERTENSION; INCIDENCE; MALE; PENNSYLVANIA; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; YOUNG ADULT;

EID: 84906050670     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114539713     Document Type: Article

References (40)

1. Secrest AM, Prince CT, Costacou T, et al. Predictors of and survival after incident stroke in type 1 diabetes. Diab Vasc Dis Res. 2013 ; 10: 3-10
2. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001 ; 44: S54 - S64
3. Laing SP, Swerdlow AJ, Carpenter LM, et al. Mortality from cerebrovascular disease in a cohort of 23,000 patients with insulin-treated diabetes. Stroke. 2003 ; 34: 418-421
4. Davis TM, Bruce DG, Davis WA. Predictors of first stroke in type 1 diabetes: the Fremantle Diabetes Study. Diabet Med. 2005 ; 22: 551-553
5. Staals J, Pieters BMA, Knottnerus ILH, et al. Haptoglobin polymorphism and lacunar stroke. Curr Neurovasc Res. 2008 ; 5: 153-158
6. Rouhl RP, van Oostenbrugge RJ, Damoiseaux JG, et al. Haptoglobin phenotype may alter endothelial progenitor cell cluster formation in cerebral small vessel disease. Curr Neurovasc Res. 2009 ; 6: 32-41
7. Staals J, Henskens LHG, Delanghe JR, et al. Haptoglobin phenotype correlates with the extent of cerebral deep white matter lesions in hypertensive patients. Curr Neurovasc Res. 2010 ; 7: 1-5
8. Costacou T, Levy AP. Haptoglobin genotype and its role in diabetic cardiovascular disease. J Cardiovasc Transl Res. 2012 ; 5: 423-435
9. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996 ; 42: 1589-1600
10. Asleh R, Marsh S, Shilkrut M, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003 ; 92: 1193-1200
11. Asleh R, Guetta J, Kalet-Litman S, et al. Haptoglobin genotype and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circ Res. 2005 ; 96: 435-441
12. Levy AP, Purushothaman KR, Levy NS, et al. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res. 2007 ; 101: 106-110
13. Levy AP. Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. Pharmacol Ther. 2006 ; 112: 501-512
14. Asleh R, Blum S, Kalet-Litman S, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes. 2008 ; 57: 2794-2800
15. Cahill LE, Levy AP, Chiuve SE, et al. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol. 2013 ; 61: 728-737
16. Simpson M, Snell-Bergeon JK, Kinney GL, et al. Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with type 1 diabetes. Cardiovasc Diabetol. 2011 ; 10: 99
17. Suleiman M, Aronson D, Asleh R, et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes. 2005 ; 54: 2802-2806
18. Levy AP, Gerstein H, Lotan R, et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care. 2004 2767 ; 27 :
19. Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol. 2008 ; 28: 341-347
20. Blum S, Vardi M, Levy NS, et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis. 2010 ; 211: 25-27
21. Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications of IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990 ; 39: 1116-1124
22. Borhani NO, Kass EH, Langford HG, et al. The hypertension detection and follow-up program. Prev Med. 1976 ; 5: 207-215
23. Warnick GR, Albers JJ. Heparin-Mn2+ quantitation of high density lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem. 1978 ; 24: 900-904
24. Allain CC, Poon LS, Chan CSG, et al. Enzymatic determination of total serum cholesterol. Clin Chem. 1974 ; 20: 470-475
25. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973 ; 19: 476-482
26. Ellis D, Buffone GJ. A new approach to the evaluation of proteinuric states. Clin Chem. 1977 ; 23: 666-670
27. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 ; 150: 604-612
28. Koch W, Latz W, Eichinger M, et al. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem. 2002 ; 48: 1377-1382
29. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes. 2008 ; 57: 1702-1706
30. Levy NS, Vardi M, Blum S, et al. An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype. Clin Chem Lab Med. 2013 ; 51: 1615-1622
31. Levy AP. Haptoglobin genotype and vascular complications in patients with diabetes. N Engl J Med. 2000 ; 343: 969-970
32. Levy AP, Hochberg I, Jablonski K, et al. Haptoglobin genotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. J Am Coll Cardiol. 2002 ; 40: 1984-1990
33. Roguin A, Koch W, Kastrati A, et al. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care. 2003 ; 26: 2628-2631
34. Costacou T, Ferrell RE, Ellis D, et al. Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes. 2009 ; 58: 2904-2909
35. Orchard TJ, Sun W, Cleary P, et al. The DCCT/EDIC Research Group. Haptoglobin genotype and the rate of renal function decline in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes. 2013 ; 62: 3218-3223
36. Engström G, Hedblad B, Janzon L, et al. Fatality of acute coronary events in relation to hypertension and low-grade inflammation: a population-based cohort study. J Hum Hypertens. 2006 ; 20: 581-586
37. Coelho C, Guerra A, Rego C, et al. Genetic polymorphisms of angiotensin-I converting enzyme, haptoglobin and angiotensinogen and oxidative stress parameters in 12 to 15-year-old adolescents. Rev Port Cardiol. 2006 ; 25: 677-690
38. Delanghe JR, Duprez DA, De Buyzere ML, et al. Haptoglobin polymorphism and complications in established essential arterial hypertension. J Hypertens. 1993 ; 11: 861-867
39. Delanghe JR, Duprez DA, De Buyzere ML, et al. Refractory hypertension is associated with the haptoglobin 2-2 phenotype. J Cardiovasc Risk. 1995 ; 2: 131-136
40. Vardi M, Blum S, Levy AP. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Eur J Intern Med. 2012 ; 23: 628-632